Before you read. This guide is educational and does not replace your Medication Guide, pharmacist, prescriber, diagnosis, or emergency care. It does not recommend Foundayo over any other medicine, and it is not a substitute for the current label.
Quick answer
Foundayo is the brand name for orforglipron, a once-daily GLP-1 receptor agonist tablet from Eli Lilly. The FDA approved it on 1 April 2026 for adults with obesity, or adults with overweight who have at least one weight-related medical condition, alongside a reduced-calorie diet and increased physical activity.
The thing that makes it structurally different from the GLP-1 pills that came before it: the label says to take it once daily, with or without food. No empty stomach. No morning-only rule. No limit on how much water you drink with it. Oral semaglutide — Wegovy tablets and Rybelsus — requires all three, plus a 30-minute wait before you can eat, drink anything else, or take other oral medicines.
That difference is not marketing. It falls out of the chemistry, and it is the single most useful thing to understand about this drug.
Why does Foundayo have no fasting rule?
Because it is a fundamentally different kind of molecule.
Semaglutide is a peptide — a modified protein chain with a molecular weight of about 4,114 g/mol. Your stomach is built to take proteins apart, so a semaglutide tablet has to be co-formulated with an absorption enhancer called SNAC, and even then the absolute bioavailability of the tablet is estimated at roughly 1% to 2%. That thin margin is why the instructions are so strict: an empty stomach, no more than 4 ounces of plain water, nothing else to drink, and a 30-minute wait afterwards. Anything in the stomach competes with a process that barely works.
Orforglipron is a small molecule — non-peptide, and roughly a quarter the size: the label gives orforglipron calcium a molecular weight of 902.0 g/mol. It does not need protecting from your digestion. Its measured absolute bioavailability was 77% after a 0.8 mg dose. Peak concentration arrives 4 to 8 hours after the dose, and the elimination half-life is roughly 29 to 49 hours.
The label states that no clinically relevant food effect on orforglipron exposure was observed. The study behind that statement used multiple doses of an investigational 37.5 mg tablet: taking it with food lowered 24-hour exposure by 19% and peak concentration by 26% compared with the fasted state, with time-to-peak and half-life unchanged. That is a measurable difference the FDA judged not clinically relevant — which is why the instruction is "with or without food" rather than a fasting window.
Same drug class, same receptor, completely different logistics. If you have lived with the 30-minute wait that oral semaglutide requires, this is the part that will feel unfamiliar.
How is Foundayo different from the other GLP-1 pills?
| Foundayo (orforglipron) | Wegovy tablets / Rybelsus (oral semaglutide) | |
|---|---|---|
| Molecule type | Small molecule, non-peptide | Peptide, co-formulated with SNAC |
| Absolute bioavailability | About 77% | About 1–2% |
| Empty stomach required | No — label says with or without food | Yes |
| Time of day | No restriction stated in the label | Morning |
| Water | No restriction stated in the label | Up to 4 ounces of plain water, nothing else |
| Wait after the dose | None stated | At least 30 minutes before food, other beverages, or other oral medicines |
| Frequency | Once daily | Once daily |
| Swallow whole | Yes — do not break, crush, or chew | Yes — do not split, crush, chew, or dissolve |
| Storage | Room temperature, 20–25 °C; light sensitive — keep in the original bottle and carton | Room temperature, 20–25 °C; keep in the original bottle to protect from moisture |
A note on wording. The label's administration instruction is "Take FOUNDAYO orally once daily, with or without food." It simply does not impose a time-of-day or water restriction — and Lilly's approval announcement describes it as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Both statements say the same thing from different directions: there is no window to protect.
If you want the fuller side-by-side across all four oral brands, we keep that in the oral GLP-1 comparison. And if you are weighing a pill against a weekly pen rather than against another pill, Wegovy pill vs injection covers that trade directly.
The honest version — "easier to take" is not the same as "works better."
No published head-to-head trial compares Foundayo with oral semaglutide, and this page does not claim one outperforms the other. What is documented is a difference in how the two fit into a day. Whether that matters more or less than everything else your prescriber is weighing is a question for the appointment, not for a comparison table.
How is Foundayo dosed?
Foundayo comes in six tablet strengths — 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg — and it steps up slowly, for the same reason every GLP-1 does: to reduce the risk of gastrointestinal side effects.
The label's escalation runs like this. Start at 0.8 mg once daily. After at least 30 days, increase to 2.5 mg once daily. After at least 30 days on 2.5 mg, increase to 5.5 mg once daily. From there the dose may be increased to the next level — 9 mg, then 14.5 mg, then 17.2 mg — after at least 30 days on the current dose, based on treatment response and tolerability. The maximum is 17.2 mg once daily.
Note the phrase "may be increased." Unlike a fixed titration to a single target, the label leaves the upper steps as a judgement call between you and your prescriber. Several of the studied maintenance doses sit below the maximum.
Swallow tablets whole; do not break, crush, or chew them. Do not take more than one tablet per day.
Missed dose: the label says to take it as soon as possible and not to double up the next dose. If 7 or more consecutive doses are missed, it directs the prescriber to reinitiate escalation at a lower dose to reduce the risk of gastrointestinal reactions — so a long gap is worth reporting rather than quietly resuming.
Built for daily GLP-1 pills. Takely handles both kinds of oral GLP-1 routine — the ones with a fasting window and the ones without — and keeps a private record of how the days actually went. Open Takely →
What are the side effects?
The same family you would expect from a GLP-1, and they are not mild for everyone.
The label pools two placebo-controlled trials covering 3,155 adults treated for up to 72 weeks. Reactions reported in at least 5% of treated patients, shown here as placebo / 5.5 mg / 9 mg / 17.2 mg:
| Adverse reaction | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Dyspepsia | 4% | 12% | 16% | 13% |
| Abdominal pain | 7% | 13% | 14% | 14% |
| Headache | 7% | 8% | 9% | 9% |
| Abdominal distension | 3% | 7% | 9% | 8% |
| Fatigue | 4% | 6% | 7% | 9% |
| Eructation | 1% | 6% | 8% | 8% |
| Gastroesophageal reflux disease | 2% | 6% | 6% | 7% |
| Flatulence | 2% | 5% | 6% | 6% |
| Hair loss | 2% | 4% | 4% | 5% |
Overall, 8% of treated patients stopped because of an adverse reaction, versus 3% on placebo, and the rate rose with dose (6% at 5.5 mg, 9% at 9 mg, 10% at 17.2 mg). Gastrointestinal reactions of any kind occurred in 60%, 68%, and 69% of patients across the three doses, against 37% on placebo. Of the patients who reported GI reactions, 60% described them as mild, 36% moderate, and 4% severe — and the label notes that the incidence of nausea, vomiting, and diarrhea was highest during escalation and decreased over time.
That last sentence is the one worth remembering during month two. It is a documented pattern, not a promise about your particular stomach.
Foundayo carries a boxed warning about the risk of thyroid C-cell tumors. Its wording is unusual and worth reading rather than skimming: orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, but because rodent thyroid C-cell tumors are considered a GLP-1 receptor-dependent effect and orforglipron is active at the human GLP-1 receptor, the human relevance has not been determined.
The label's other warnings and precautions include acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia when combined with insulin or an insulin secretagogue, hypersensitivity reactions, diabetic retinopathy complications in type 2 diabetes, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation.
Who is it not for?
Foundayo is contraindicated in people with a personal or family history of medullary thyroid carcinoma, in people with Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a known serious hypersensitivity to orforglipron or the tablet's excipients.
Beyond the contraindications, the label flags several situations to raise with a prescriber:
- Pregnancy. May cause fetal harm; the label directs that Foundayo be discontinued when pregnancy is recognised.
- Breastfeeding. Not recommended for nursing women.
- Oral hormonal contraception. This one surprises people. Because Foundayo delays gastric emptying and its effect on oral contraceptive absorption has not been studied in a clinical trial, the label advises switching to a non-oral method, or adding a barrier method, for 30 days after starting Foundayo and for 30 days after each dose escalation. Non-oral hormonal contraceptives should not be affected.
- Other oral medicines. Delayed gastric emptying can affect the absorption of anything else you swallow.
- Certain drug interactions. The maximum dose is 9 mg daily when used with a strong CYP3A4 inhibitor; strong CYP3A4 inhibitors that also inhibit OATP1B should be avoided, as should strong CYP3A4 inducers; and simvastatin should not exceed 20 mg daily alongside Foundayo.
- Severe hepatic impairment. Not recommended.
- Children. Safety and effectiveness have not been established in pediatric patients.
- Other GLP-1s. Concomitant use with another GLP-1 receptor agonist is not recommended.
What was it tested on?
Two 72-week randomized, double-blind, placebo-controlled trials support the approval.
Trial 1 (NCT05869903, known as ATTAIN-1) enrolled 3,127 adults with obesity, or overweight plus at least one weight-related condition such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease. People with type 2 diabetes were excluded. Trial 2 (NCT05872620, ATTAIN-2) enrolled 1,613 adults with a BMI of 27 or higher and type 2 diabetes. Both randomized participants to 5.5 mg, 9 mg, or 17.2 mg once daily or placebo, with everyone receiving reduced-calorie diet instruction and physical activity counselling. The primary endpoint in both was mean percent change in body weight at week 72.
The full results — including the weight-change figures, the cardiometabolic endpoints, and the confidence intervals — are in the label's clinical studies section and in the ATTAIN-1 publication in the New England Journal of Medicine, both linked below. We are deliberately not reprinting the headline weight numbers here: they are trial averages under trial conditions, they say nothing about any individual, and the right place to discuss what is realistic for you is with a prescriber.
One point that matters if you are comparing Foundayo with anything else you have read about: these were placebo-controlled trials, not head-to-head trials against another GLP-1. Numbers from one drug's trial cannot be lined up against numbers from another drug's trial and read as a comparison. Different participants, different sites, different years.
What does a day on Foundayo actually look like?
Simpler than the alternatives, which creates its own problem.
With oral semaglutide, the fasting window is annoying but it is also a scaffold: the rule forces the dose to happen at a fixed point in the morning. Foundayo removes the scaffold. Once daily, any time, with or without food, is easy to take and easy to forget.
So the useful habit is not a timer — it is an anchor. Attach the tablet to something that already happens every single day at roughly the same time, and pick something that survives a weekend. The dose being flexible does not mean it should float.
Two other things worth logging in the first few months, because both come up at follow-up appointments: how the GI symptoms track against each dose step, and the dates of your escalations — which matter for the 30-day contraception guidance above. If you want that captured without a food diary, Takely is built for exactly this shape of routine.
Frequently asked questions
What is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist tablet from Eli Lilly. The FDA approved it on 1 April 2026 for adults with obesity, or adults with overweight and at least one weight-related medical condition, in combination with a reduced-calorie diet and increased physical activity.
Do I have to take Foundayo on an empty stomach?
No. The label instruction is to take it orally once daily, with or without food. That is the main practical difference between Foundayo and oral semaglutide, which requires an empty stomach, up to 4 ounces of plain water, and a 30-minute wait.
Can I take Foundayo at night?
The label does not restrict the time of day, and Lilly describes it as able to be taken any time of day. Consistency still helps — pick a time you can repeat — and confirm the plan with your prescriber.
Is Foundayo the same as Wegovy or Ozempic?
No. Those contain semaglutide, a peptide. Foundayo contains orforglipron, a small non-peptide molecule. All are GLP-1 receptor agonists, and the label says using Foundayo alongside another GLP-1 receptor agonist is not recommended.
Is Foundayo a weekly pill?
No. It is once daily.
What if I miss a dose of Foundayo?
The label says to take it as soon as possible and not to double up the next dose. If 7 or more consecutive doses are missed, the label directs the prescriber to reinitiate escalation at a lower dose — so tell them rather than restarting at your old dose.
How much does Foundayo cost?
Lilly's launch announcement stated pricing starting at $25 per month with commercial coverage through the Foundayo savings card, and $149 per month self-pay for the lowest dose, with Foundayo available through LillyDirect, telehealth providers, and US retail pharmacies from 9 April 2026. It also stated that eligible Medicare Part D beneficiaries may be able to get Foundayo for $50 per month beginning 1 July 2026. Prices, tiers, and eligibility change frequently — check the manufacturer's current terms and your own plan.
Primary sources and further reading
- FDA Prescribing Information — FOUNDAYO (orforglipron) tablets, revised 04/2026 ↗
- Eli Lilly — FDA approves Foundayo (orforglipron), 1 April 2026 ↗
- Eli Lilly — Foundayo now available in the U.S., 9 April 2026 ↗
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) — N Engl J Med 2025;393:1796–1806, PMID 40960239 ↗
- FDA Prescribing Information — WEGOVY (semaglutide) injection and tablets, revised 12/2025 ↗
- FDA Prescribing Information — RYBELSUS (semaglutide) tablets, revised 10/2025 ↗
Foundayo is a new medicine and its label, pricing, and coverage will change. Everything on this page was verified against the sources above on 31 July 2026. Check the current label and ask your clinician or pharmacist about your own prescription.